ArticleParasites & vectors2026
Ectoparasitic prevention compliance in dogs based on prescription records from veterinary practices in Poland.
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFleas and ticks are common and harmful ectoparasites in dogs. They feed on blood, cause irritation, and transmit various pathogens. In Poland, the primary species Ctenocephalides felis (fleas), Ixodes ricinus, and Dermacentor reticulatus (ticks) pose a year-round threat. Veterinary organizations recommend continuous year-round protection against ectoparasites. However, actual owner compliance with this recommendation remains unknown.
methodsThis retrospective study analyzed medical records from 2021 to 2023 across 45 veterinary practices in Poland. A total of 44,140 ectoparasiticide prescriptions were reviewed for 19,351 unique dogs. Products were categorized by active ingredient and duration of efficacy into four groups: 12-week isoxazolines, monthly isoxazolines, non-isoxazoline products, and collars. Protection coverage was estimated based on the number of doses prescribed and the labeled duration of each product, assuming all medications were administered on time, starting on the date of purchase.
resultsThe mean duration of protection against ticks over 3 years was 42.0 weeks for collars, 27.5 weeks for 12-week isoxazolines, 14.2 weeks for monthly isoxazolines, and 6.7 weeks for non-isoxazoline products. All durations were significantly different. Overall, the average protection provided to all dogs in the study was only 22.5% of the recommended year-round coverage. Most dogs received only one dose per year. Only 9.1% of dogs received at least one dose annually for three consecutive years, and just 0.1% received complete (> 150 weeks) year-round protection for all 3 years.
conclusionsThese findings indicate that compliance with year-round ectoparasitic protection in Poland is significantly below recommended levels. Most dogs are not adequately protected throughout the year, and very few receive consistent protection over multiple years. This leaves a substantial portion of the canine population vulnerable to ectoparasitic infestations and vector-borne diseases. Veterinary clinics must adopt objective compliance tracking and proactively develop and refine communication strategies to enhance adherence to parasite prevention protocols and minimize the risk of parasite-related health issues in dogs, and consider the role of longer-acting parasiticides to improve adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.